RGX-019

RGX-019 is an investigational drug candidate. Rgenix is developing RGX-019, a monoclonal antibody that targets MerTK, for the treatment of solid tumors.  Rgenix in-licensed RGX-019 and other antibody intellectual property from Rockefeller University as part of a world-wide exclusive licensing agreement.

Rgenix identified MerTK as a novel cancer target in triple-negative breast cancer (TNBC) in collaboration with the Rockefeller University by using the company’s proprietary target discovery platform.¹  MerTK is a receptor tyrosine kinase of the TAM family and is over-expressed in several human cancers.²  The MerTK pathway drives cancer progression, tumor angiogenesis, and innate immune activation^2,3  Targeting MerTK affects tumor associated macrophage polarization in part by changing them from a pro-tumorigenic M2 state to an anti-tumorigenic M1 state.  Rgenix plans to initiate IND-enabling studies of RGX-019 in 2019.